Table 2 Correlations between cfDNA concentrations and clinical features.

From: Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing

Clinical feature

Parameter value

n

cfDNA concentration avg ± SD (ng/ml)

p-valuea

Age

<65

27

5.64 ± 10.71

0.303

≥65

31

7.4 ± 11.54

Sex

Female

25

9.6 ± 13.42

0.318

Male

33

4.29 ± 8.47

GGO

N

50

7.53 ± 11.69

0.05

Y

8

0.66 ± 0.7

Differentiation level

Median or high

44

5.35 ± 9.16

0.138

Poor

14

10.44 ± 15.53

Vascular invasion

N

51

6.46 ± 11.17

0.383

Y

7

7.49 ± 11.41

VPI

N

48

6.11 ± 10.6

0.458

Y

10

8.85 ± 13.65

Histology

SCC

7

10.11 ± 12.93

0.671

AC

51

5.66 ± 10.54

Stage

I

46

4.57 ± 7.74

0.05

II

12

14.28 ± 17.66

  1. GGO: ground glass opacity; VPI: visceral pleural involvement; SCC: squamous cell carcinoma; AC: adenocarcinoma.
  2. aMann-Whitney U test.
Back to article page